Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery. The LYNX-2 trial is being conducted under conditions of a Special Protocol Assessment with the U.S. Food and Drug Administration. As previously announced, Ocuphire received written agreement from the FDA that the clinical trial protocol and planned statistical analysis of the LYNX-2 Phase 3 trial would adequately address objectives supporting regulatory submission and a potential future marketing application in this indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
- Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
- Ocuphire Pharma announces U.S. commercial launch of RYZUMVI
- Ocuphire Pharma Engages Investors with Presentation Update
- Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global